Clinical Trials
13 trialsNCT04940052 2026-06-04
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
Novartis
Phase 3 Active not recruiting
NCT03975829 2026-06-02
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Recruiting
NCT01682083 2026-04-21
COMBI-AD
Novartis
Phase 3 Completed
NCT03340506 2026-04-20
Dabrafenib and/or Trametinib Rollover Study
Novartis
Phase 4 Recruiting
NCT04666272 2026-02-19
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
Novartis
Active not recruiting
NCT04452877 2026-01-13
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
Novartis
Phase 2 Completed
NCT06262919 2025-12-30
Special Drug Use-results Surveillance of Tafinlar/Mekinist
Novartis
Recruiting
NCT04294160 2025-12-24
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
Phase 1 Terminated
NCT04489433 2025-12-18
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
Novartis
No longer available
NCT04961619 2025-12-12
LEAD Melanoma
Novartis
Completed
NCT02967692 2025-09-18
COMBI-i
Novartis
Phase 3 Terminated
NCT04418167 2025-09-03
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
Phase 1 Suspended
NCT05585320 2025-09-02
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
Phase 1/2 Active not recruiting